poisar

Stocks · News reference

Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14

Jul 22, 2026, 10:36 AMBenzinga News-desk

Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III StudySummit Therapeutics Inc. (NASDAQ:SMMT) today announced results of an updated overall survival (OS) analysis from the

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SMMT
Source
benzinga
Observed
Jul 22, 2026, 10:36 AM
Checked
Jul 22, 2026, 10:36 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK